- Management will present and hold virtual 1-on-1 meetings with institutional investors and analysts
Event: H.C. Wainwright Presentation On-Demand
Date:
Time:
Registration: Link
*Please note that Company presentation date and time are subject to change. Attendees may refer to the program agenda for more information. Once the presentation becomes available on-demand, registered attendees can submit their Q&As for the Company.
About
Forward Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend” or other similar terms or expressions that concern Hillstream’s expectations, strategy, plans or intentions. These forward-looking statements are based on Hillstream’s current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; risks related to business interruptions, including the outbreak of COVID-19 coronavirus, which could seriously harm our financial condition and increase our costs and expenses; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. Investors should read the risk factors set forth in our Form 10-K for the year ended
“Picobody” is a trademark of
Investor Relations Contact
Email: investorrelations@hillstreambio.com
www.hillstreambio.com
Source:
2023 GlobeNewswire, Inc., source